Shunichiro Hanai

Chuo, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 50 publications

Comment on: "A narrative review of the diagnostic role of muscle biopsy in small- to medium-vessel vasculitis: Consideration of imaging-guided procedures".

Comment on: "A narrative review of the diagnostic role of muscle biopsy in small- to medium-vessel vasculitis: Consideration of imaging-guided procedures".

Journal: Modern rheumatology
Published: July 22, 2026

Efficacy and safety of filgotinib versus tocilizumab in active rheumatoid arthritis: A randomized, open-label, multicenter study with clinical and musculoskeletal ultrasound evaluation (TRANSFORM study).

Efficacy and safety of filgotinib versus tocilizumab in active rheumatoid arthritis: A randomized, open-label, multicenter study with clinical and musculoskeletal ultrasound evaluation (TRANSFORM study).

Journal: Drug discoveries & therapeutics
Published: April 26, 2026

Clinical outcomes of anifrolumab after belimumab failure in systemic lupus erythematosus: A single-center case series.

Clinical outcomes of anifrolumab after belimumab failure in systemic lupus erythematosus: A single-center case series.

Journal: Lupus
Published: April 13, 2026

Regression of a Refractory Pulmonary Lesion in Granulomatosis with Polyangiitis Following the Addition of Avacopan.

Regression of a Refractory Pulmonary Lesion in Granulomatosis with Polyangiitis Following the Addition of Avacopan.

Journal: European journal of rheumatology
Published: February 27, 2026

Clinical relevance of serum lysozyme in sarcoidosis with kidney impairment.

Clinical relevance of serum lysozyme in sarcoidosis with kidney impairment.

Journal: Immunological medicine
Published: February 05, 2026

Life-threatening hemorrhage from acquired factor V deficiency with non-inhibitory, hyperclearance-type antibodies successfully treated with rituximab followed by belimumab.

Life-threatening hemorrhage from acquired factor V deficiency with non-inhibitory, hyperclearance-type antibodies successfully treated with rituximab followed by belimumab.

Journal: Joint bone spine
Published: February 05, 2026

Sublingual allergen immunotherapy in immunosuppressed rheumatoid arthritis patients: Safety and clinical outcomes.

Sublingual allergen immunotherapy in immunosuppressed rheumatoid arthritis patients: Safety and clinical outcomes.

Journal: The journal of allergy and clinical immunology. Global
Published: December 22, 2025

Pancytopenia and splenomegaly as uncommon manifestations in a patient with immunoglobulin G4-related disease.

Pancytopenia and splenomegaly as uncommon manifestations in a patient with immunoglobulin G4-related disease.

Journal: Modern rheumatology case reports
Published: November 18, 2025

Dr. Harama et al reply.

Dr. Harama et al reply.

Journal: The Journal of rheumatology
Published: November 15, 2025

Bone Erosion Repair With a Janus Kinase Inhibitor.

Bone Erosion Repair With a Janus Kinase Inhibitor.

Journal: The Journal of rheumatology
Published: November 01, 2025

Life-threatening refractory leukopenia in a patient with systemic lupus erythematosus successfully treated with rituximab.

Life-threatening refractory leukopenia in a patient with systemic lupus erythematosus successfully treated with rituximab.

Journal: Immunological medicine
Published: September 17, 2025

Risk of Kidney Impairment during Iguratimod Therapy for Rheumatoid Arthritis Patients: The Role of Concomitant Salazosulfapyridine.

Risk of Kidney Impairment during Iguratimod Therapy for Rheumatoid Arthritis Patients: The Role of Concomitant Salazosulfapyridine.

Journal: Internal medicine (Tokyo, Japan)
Published: September 03, 2025
Showing 1-12 of 50

Last Updated: 09/26/2026